These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36146626)

  • 1. Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection.
    Dimeglio C; Migueres M; Bouzid N; Chapuy-Regaud S; Gernigon C; Da-Silva I; Porcheron M; Martin-Blondel G; Herin F; Izopet J
    Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diminished Neutralization Capacity of SARS-CoV-2 Omicron BA.1 in Donor Plasma Collected from January to March 2021.
    Lin YJ; Evans DH; Robbins NF; Orjuela G; Abe KT; Rathod B; Colwill K; Gingras AC; Tuite A; Yi QL; O'Brien SF; Drews SJ
    Microbiol Spectr; 2023 Aug; 11(4):e0525622. PubMed ID: 37289096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5.
    Bormann M; Brochhagen L; Alt M; Otte M; Thümmler L; van de Sand L; Kraiselburd I; Thomas A; Gosch J; Braß P; Ciesek S; Widera M; Dolff S; Dittmer U; Witzke O; Meyer F; Lindemann M; Schönfeld A; Rohn H; Krawczyk A
    Front Immunol; 2023; 14():1150667. PubMed ID: 37520539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of protection against SARS-CoV-2 Omicron BA.1 and Delta infections in fully vaccinated outpatients.
    Roy A; Saade C; Josset L; Clément B; Morfin F; Destras G; Valette M; Icard V; Billaud G; Oblette A; Debombourg M; Garrigou C; Brengel-Pesce K; Generenaz L; Saker K; Hernu R; Pozzetto B; Lina B; Trabaud MA; Trouillet-Assant S; Bal A
    J Med Virol; 2023 Aug; 95(8):e28984. PubMed ID: 37503561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays.
    Seidel A; Hoffmann S; Jahrsdörfer B; Körper S; Ludwig C; Vieweg C; Albers D; von Maltitz P; Müller R; Lotfi R; Wuchter P; Klüter H; Kirchhoff F; Schmidt M; Münch J; Schrezenmeier H
    Front Immunol; 2023; 14():1170759. PubMed ID: 37180152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing Antibody Responses against Five SARS-CoV-2 Variants and T Lymphocyte Change after Vaccine Breakthrough Infections from the SARS-CoV-2 Omicron BA.1 Variant in Tianjin, China: A Prospective Study.
    Zhang Y; Qu JW; Zheng MN; Ding YX; Chen W; Ye SD; Li XY; Li YK; Liu Y; Zhu D; Jin CR; Wang L; Yang JY; Zhai Y; Wang EQ; Meng X
    Biomed Environ Sci; 2023 Jul; 36(7):614-624. PubMed ID: 37533385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-dependent NK-cell and neutralizing antibody responses against the Spike protein of Wuhan-Hu-1 and Omicron BA.1 SARS-CoV-2 variants in vaccinated experienced and vaccinated naïve individuals.
    Albert E; Fernández-Soto D; Giménez E; Casanovas JM; Zulaica J; Álvarez-Rodríguez B; Rusu L; Geller R; Reyburn HT; Navarro D
    J Med Virol; 2023 Jul; 95(7):e28900. PubMed ID: 37403730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants.
    Duty JA; Kraus T; Zhou H; Zhang Y; Shaabani N; Yildiz S; Du N; Singh A; Miorin L; Li D; Stegman K; Ophir S; Cao X; Atanasoff K; Lim R; Mena I; Bouvier NM; Kowdle S; Carreño JM; Rivero-Nava L; Raskin A; Moreno E; Johnson S; Rathnasinghe R; Pai CI; Kehrer T; Cabral EP; Jangra S; Healy L; Singh G; Warang P; Simon V; Sordillo EM; van Bakel H; Liu Y; Sun W; Kerwin L; Teijaro J; Schotsaert M; Krammer F; Bresson D; García-Sastre A; Fu Y; Lee B; Powers C; Moran T; Ji H; Tortorella D; Allen R
    Med; 2022 Oct; 3(10):705-721.e11. PubMed ID: 36044897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.
    Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W
    Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections.
    Medits I; Springer DN; Graninger M; Camp JV; Höltl E; Aberle SW; Traugott MT; Hoepler W; Deutsch J; Lammel O; Borsodi C; Puchhammer-Stöckl E; Zoufaly A; Weseslindtner L; Aberle JH; Stiasny K
    Front Immunol; 2022; 13():946318. PubMed ID: 35928813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty® COVID-19 vaccine: Looking for correlates of protection.
    Torres I; Giménez E; Albert E; Zulaica J; Álvarez-Rodríguez B; Burgos JS; Peiró S; Limón R; Vanaclocha H; Rodado C; Botija P; Sifre A; Tur B; Lozano RA; Orosa I; Vicente-Ruiz M; Carrión RJ; Clari MÁ; Sánchez-Payá J; Díez-Domingo J; Comas I; González-Candelas F; Geller R; Navarro D;
    J Med Virol; 2022 Sep; 94(9):4216-4223. PubMed ID: 35585782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of SARS-CoV-2 antibodies after confirmed Omicron BA.1 and presumed BA.4/5 infections using Abbott ARCHITECT and Panbio assays.
    Boler M; Anderson M; Rodgers M; Parumoottil J; Olivo A; Harris B; Stec M; Gosha A; Behun D; Holzmayer V; Anderson A; Greenholt E; Fortney T; Almaraz E; Cloherty G; Landay A; Moy J
    IJID Reg; 2023 Jun; 7():277-280. PubMed ID: 37234563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A machine learning model for predicting serum neutralizing activity against Omicron SARS-CoV-2 BA.2 and BA.4/5 sublineages in the general population.
    Camacho J; Albert E; Álvarez-Rodríguez B; Rusu L; Zulaica J; Moreno AR; Peiró S; Geller R; Navarro D; Giménez E
    J Med Virol; 2023 Apr; 95(4):e28739. PubMed ID: 37185857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors Associated With Protection From SARS-CoV-2 Omicron Variant Infection and Disease Among Vaccinated Health Care Workers in Israel.
    Gilboa M; Gonen T; Barda N; Cohn S; Indenbaum V; Weiss-Ottolenghi Y; Amit S; Asraf K; Joseph G; Levin T; Kanaaneh Y; Aydenzon A; Canetti M; Freedman L; Zuckerman N; Mendelson E; Doolman R; Kreiss Y; Regev-Yochay G; Lustig Y
    JAMA Netw Open; 2023 May; 6(5):e2314757. PubMed ID: 37219906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prediction of protection probability against Omicron BA.1, BA.4 and BA.5 variants in symptomatic infections with prototype strain based on neutralization antibody levels].
    Lu WY; Chen XH; Zheng N; Yu HJ
    Zhonghua Yi Xue Za Zhi; 2023 May; 103(18):1429-1434. PubMed ID: 37150697
    [No Abstract]   [Full Text] [Related]  

  • 16. Decreased Efficiency of Neutralizing Antibodies from Previously Infected or Vaccinated Individuals against the B.1.617.2 (Delta) SARS-CoV-2 Variant.
    Dimeglio C; Herin F; Da-Silva I; Gernigon C; Porcheron M; Chapuy-Regaud S; Izopet J
    Microbiol Spectr; 2022 Aug; 10(4):e0270621. PubMed ID: 35867411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong.
    Zhou R; Liu N; Li X; Peng Q; Yiu CK; Huang H; Yang D; Du Z; Kwok HY; Au KK; Cai JP; Fan-Ngai Hung I; Kai-Wang To K; Xu X; Yuen KY; Chen Z
    Lancet Reg Health West Pac; 2023 Mar; 32():100660. PubMed ID: 36591327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model.
    Ma J; Liu X; Zhou M; Chen P; Chen R; Wang J; Zhu H; Wu K; Ye J; Zhang Y; Yuan Q; Tang Q; Yuan L; Cheng T; Guan Y; Xia N
    J Virol; 2023 Feb; 97(2):e0168422. PubMed ID: 36651747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long term anti-SARS-CoV-2 antibody kinetics and correlate of protection against Omicron BA.1/BA.2 infection.
    Perez-Saez J; Zaballa ME; Lamour J; Yerly S; Dubos R; Courvoisier DS; Villers J; Balavoine JF; Pittet D; Kherad O; Vuilleumier N; Kaiser L; Guessous I; Stringhini S; Azman AS;
    Nat Commun; 2023 May; 14(1):3032. PubMed ID: 37230973
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.